Milan, 28(th)November 2011 - Pursuant to Article 2.6.2, paragraph 1, letter c) of Borsa Italiana S.p.A.'s Regulation, Recordati S.p.A. hereby communicates the calendar of corporate events for 2012. 9(th)  February      Board of Directors' meeting to approve the 2011 preliminary consolidated results. 8(th ) March            Board of Directors' meeting to approve the 2011 consolidated financial statements and  the draft of Recordati S.p.A.'s 2011 financial statements. 19(th  )April            Shareholders' General Meeting to approve the 2011 Financial Statements. 8(th ) May                               Board of Directors' meeting to approve the 2012 first quarter interim management statement. 9(th) May                Presentation to financial analysts. 26(th )July                               Board of Directors' meeting to approve the 2012 half-yearly report. 25(th )October       Board of Directors' meeting to approve the 2012 first nine months' interim management statement. Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271),with a total staff of over 2,800, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. It has headquarters in Milan, Italy, operations in the main European countries, and a growing presence in the new markets of Central and Eastern Europe.  A European field force of around 1,400 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.  Consolidated revenue for 2010 was € 728.1 million, operating income was € 154.8 million and net income was € 108.6 million. For further information: Recordati website: Investor Relations                                        Media Relations Marianne Tatschke                                        Ketchum PR (39)0248787393                                        Cristina Risciotti, (39)0262411919, (39)3481343116,                                        Marzia Ongaretti, (39)0262411915, RECORDATI: 2012 CORPORATE EVENTS’ CALENDAR : This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: RECORDATI via Thomson Reuters ONE [HUG#1567271]